CG Oncology, Inc. (NASDAQ:CGON) Given Average Recommendation of “Moderate Buy” by Brokerages

CG Oncology, Inc. (NASDAQ:CGON) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $67.8333.

Several equities analysts have recently weighed in on CGON shares. The Goldman Sachs Group restated a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research report on Monday, January 12th. Truist Financial raised their target price on shares of CG Oncology from $62.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Wedbush initiated coverage on shares of CG Oncology in a research report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target on the stock. Morgan Stanley set a $93.00 price objective on CG Oncology in a research report on Friday, January 9th. Finally, Royal Bank Of Canada raised their price objective on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st.

CG Oncology Stock Performance

Shares of CGON stock opened at $54.34 on Tuesday. CG Oncology has a 1 year low of $14.80 and a 1 year high of $57.88. The business’s fifty day moving average is $45.78 and its 200-day moving average is $38.55. The stock has a market cap of $4.38 billion, a PE ratio of -26.64 and a beta of 1.35.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, meeting the consensus estimate of ($0.57). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.07 million. Equities research analysts predict that CG Oncology will post -1.31 earnings per share for the current year.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director James Mulay sold 11,145 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The SEC filing for this sale provides additional information. Company insiders own 7.40% of the company’s stock.

Institutional Trading of CG Oncology

Several large investors have recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology in the fourth quarter worth $27,000. Winthrop Capital Management LLC acquired a new position in CG Oncology during the second quarter valued at $38,000. Strengthening Families & Communities LLC purchased a new stake in CG Oncology in the 3rd quarter worth about $40,000. Comerica Bank boosted its position in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.